8.05USD
1.16 BUSD
9.42 BUSD
144.19 M
About BIOGEN INC COM STK USD0.0005
Sector
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Employees (FY)
7.57 K
Founded
1978
ISIN
US09062X1037
FIGI
BBG002JKNKF4
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Legendary Sharkley A combination of a Shark harmonic pattern and a Gartley has emerged at the pattern completion zone. There is also bullish divergence on the RSI at the comfirmation double bottom. NASDAQ:BIIB has been oscillating between around $190-$440 since 2013 and seems to be at a good bargain price of $218 cu
9 year consolidation about over?Might make this one a core position over the coming months... 200 month moving average tested successfully once already.
$BIIB ShortNASDAQ:BIIB is forming a Bearish Gartley pattern after attempting a breakout. Gartly patterns are one of the most common harmonic patterns.
Typically the stop-loss on these patterns can be set at the first leg of the pattern around the $270 mark.
BIIB Overdue for Gap UpBIIB's at a support level, but it's also been gapping up significantly every 2-6 quarters for the past few years. Its last gap was exactly a year ago, so it's overdue for a gap up. It's also within a month of earnings, so management is likely keen on pushing for newsworthy developments. I'll be roll
$BIIB: Monster trade, brace yourselvesBiogen has a monster trade brewing here, can't afford to miss this trade. I've been trading it actively since they received FDA approval for their Alzheimer's drug a while back.
The current setup looks very strong and implies a massive uptrend can start from right here.
Best of luck!
Ivan Labrie
Biogen testing channel supportBiogen Inc. (BIIB) currently testing channel support, able to absorb weekly selling pressures.
From here, (BIIB) can recover and turn higher to channel resistance, eliciting gains of 20-25% over the following 2 - 3 months.
A settlement above this week’s high would accelerate this upward momentum
BIIB earningsBiogen (BIIB) earnings are on Wednesday, July 19th, 2023, at 7:15am. Biogen (BIIB) reported Q1 March 2023 earnings of 3.40 per share on revenue of 2.5 billion. The consensus earnings estimate was 3.25 per share on revenue of 2.4 billion. The company said it continues to expect 2023 earnings of 15.00
BIIB next up target 450 and then 1080Biogen getting ready to break the long consolidation, next upside target is 450, once that is broken expect to hit 1080.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where 0R1B is featured.
Frequently Asked Questions
The current price of 0R1B is 191.60 USD — it has decreased by 1.09% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange BIOGEN INC COM STK USD0.0005 stocks are traded under the ticker 0R1B.
BIOGEN INC COM STK USD0.0005 is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
0R1B stock is 1.95% volatile and has beta coefficient of 0.74. Check out the list of the most volatile stocks — is BIOGEN INC COM STK USD0.0005 there?
One year price forecast for BIOGEN INC COM STK USD0.0005 has a max estimate of 393.00 USD and a min estimate of 213.00 USD.
0R1B earnings for the last quarter are 4.36 USD whereas the estimation was 3.97 USD which accounts for 9.73% surprise. Estimated earnings for the next quarter are 3.18 USD. See more details about BIOGEN INC COM STK USD0.0005 earnings.
BIOGEN INC COM STK USD0.0005 revenue for the last quarter amounts to 2.53 B USD despite the estimated figure of 2.40 B USD. In the next quarter revenue is expected to reach 2.47 B USD.
Yes, you can track BIOGEN INC COM STK USD0.0005 financials in yearly and quarterly reports right on TradingView.
0R1B stock has fallen by 5.09% compared to the previous week, the month change is a 11.83% fall, over the last year BIOGEN INC COM STK USD0.0005 has showed a 34.56% decrease.
0R1B net income for the last quarter is 249.70 M USD, while the quarter before that showed −68.10 M USD of net income which accounts for 466.67% change. Track more BIOGEN INC COM STK USD0.0005 financial stats to get the full picture.
Today BIOGEN INC COM STK USD0.0005 has the market capitalization of 27.93 B, it has decreased by 1.30% over the last week.
No, 0R1B doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0R1B shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN INC COM STK USD0.0005 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 7.57 K employees. See our rating of the largest employees — is BIOGEN INC COM STK USD0.0005 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN INC COM STK USD0.0005 technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN INC COM STK USD0.0005 stock shows the strong sell signal. See more of BIOGEN INC COM STK USD0.0005 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BIOGEN INC COM STK USD0.0005 future price: according to them, 0R1B price has a max estimate of 393.00 USD and a min estimate of 213.00 USD. Read a more detailed BIOGEN INC COM STK USD0.0005 forecast: see what analysts think of BIOGEN INC COM STK USD0.0005 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN INC COM STK USD0.0005 EBITDA is 2.13 B USD, and current EBITDA margin is 22.58%. See more stats in BIOGEN INC COM STK USD0.0005 financial statements.